ATXS
Astria Therapeutics, Inc.
$6.79
0.44
(6.93%)
| Exchange: | NASDAQ |
| Market Cap: | 383.193M |
| Shares Outstanding: | 144422 |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Jill C. Milne | |||||
| Full Time Employees: | 78 | |||||
| Address: |
|
|||||
| Website: | https://www.astriatx.com |
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Click to read more…
Revenue Segmentation
🔒 You are currently logged out
Income Statement
(* All numbers are in thousands)
🔒 You are currently logged out
Balance Sheet
(* All numbers are in thousands)
🔒 You are currently logged out
Cash Flow Statement
(* All numbers are in thousands)
🔒 You are currently logged out
Analyst Estimates
(* All numbers are in thousands)
🔒 You are currently logged out
Current Key Metrics
🔒 You are currently logged out
Forward P/E Ratios
🔒 You are currently logged out
SWOT Analysis
🔒 You are currently logged out
At what price to buy it? –
Intrinsic Value Calculator
🔒 Premium Feature
Log in to access the ATXS Intrinsic Value Calculator
Get comprehensive stock analysis with premium features
🔒 You are currently logged out
MS_Stock_Embed class not found. Please check plugin configuration.